SAM
ADMS

Seelaus Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Seelaus Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,100
Closed -$207K – 202
2017
Q4 		$207K Buy
+6,100
New +$170K 0.18% 158

Other funds holding ADMS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BWCA
Brenner West Capital Advisors New York $804M AUM 16.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Seelaus Asset Management's ADMS Position: Q1 2018 in Review

Seelaus Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2018, closing a stake of 6,100 shares — an estimated $207K sold.

Seelaus Asset Management first reported a position in ADMS in Q4 2017 and held it in 1 quarter. The position peaked at $207K in Q4 2017. 118 funds tracked by Wall St. Rank hold ADMS as of Q1 2018.

  • Seelaus Asset Management reported no remaining Adamas Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Seelaus Asset Management sold 6,100 Adamas Pharmaceuticals shares in Q1 2018, an estimated $207K.
  • Seelaus Asset Management first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Seelaus Asset Management's Adamas Pharmaceuticals position peaked at $207K in Q4 2017.
  • 118 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2018.

Based on Seelaus Asset Management's 13F filing for Q1 2018, filed 7 May 2018.